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Introduction: Bisphosphonates (BPs) are effective in preventing,
reducing the incidence, and delaying the onset of skeletal-related
events in patients with bone metastases in a variety of solid tumors,
including lung cancer. The purpose of this article is to review the
current evidence for the use of BPs in lung cancer and to provide
specific European recommendations to support the clinical practice
of using BPs to treat patients with lung cancer with bone metastases.
Methods: An expert panel of European clinical oncologists and lung
cancer specialists convened for two face-to-face meetings designed
to review available evidence on the efficacy of BPs in lung cancer
and to develop recommendations based on published literature and
clinical practice experiences.
Results: The panel recommends screening patients with lung cancer
for bone metastases at the initial staging of disease to assess
symptomatic bone metastases and screen for asymptomatic bone
metastases and to allow accurate monitoring of bone disease pro-
gression and initiate bone-specific therapy. Bone assessment should
be based on positron emission tomography (if available) or bone
scan. BPs should be added to the treatment of patients with lung
cancer (with non-small cell lung cancer or small cell lung cancer)
who develop bone metastases. In such patients, BPs must be con-
sidered part of metastatic lung cancer treatment to prevent and delay
the occurrence of further bone metastases and skeletal-related events
and to relieve pain where present. BP treatment should continue for
as long as it is practically feasible in the absence of any significant
adverse effects.
Key Words: Bisphosphonates, Lung cancer, Bone metastases, Skel-
etal-related events, Recommendations.
(J Thorac Oncol. 2009;4: 1280–1288)
Many patients with advanced cancer develop bone me-tastases during the course of their disease, and these are
often associated with significant morbidity. The majority of
bone metastases arise from primary tumors of the breast,
lung, or prostate. Approximately 30 to 40% of patients with
advanced non-small cell lung cancer (NSCLC) develop bone
metastases.1 The median survival time of these patients is less
than 1 year. The high mortality is predominantly due to the
difficulties in the early diagnosis of bone metastases and the
high-metastatic potential of lung cancer.
Malignant cells secrete factors, including interleukin
(IL)-1, IL-6, receptor activator of NF-kappaB (RANK) li-
gand, parathyroid hormone-related protein, and macrophage
inflammatory protein-1-alpha (MIP-1), that disturb the cou-
pling of the normal bone metabolism, leading to an increase
in bone resorption.2 As a consequence, bone metastases from
lung cancer are primarily osteolytic and result in bone lesions
that undermine the structural integrity of the skeleton and
may cause bone pain and also skeletal-related events (SREs)
that include pathologic fractures, the need for surgery or
radiotherapy, spinal cord or nerve root compression, and
hypercalcemia of malignancy3,4 (Figure 1).
A retrospective review of 435 patients with NSCLC re-
vealed an incidence of 24% for bone metastases; the majority of
bone metastases (66%) were detected at the time of initial
staging.5 In a recent retrospective study of 259 patients with
NSCLC, 70 (30.4%) were found to have bone metastases during
their clinical course. Among them, 46 patients (65.7%) had bone
metastases at the time of initial diagnosis and 35 (50%) suffered
from SREs. Thirty-one percent of the patients with SREs already
had them at the time of initial staging, whereas 69% of this
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patient cohort developed SREs due to recurrence of their disease
after treatment.6 Bone pain is the most common symptom
resulting from bone metastases in patients with lung cancer and
occurs in around 80% of patients.7
Patients with bone metastases arising from lung cancer
can experience up to four SREs per year, with the risk of
developing subsequent SREs increasing after the first event.8–14
In addition, patients with metastatic bone disease from lung
cancer who developed SREs had a 50% shorter survival, when
compared with patients who did not develop SREs.15
Most of the patients who suffer from SREs need radi-
ation therapy or surgical interventions. These events often
lead to rapid deterioration in quality of life (QoL) could
eventually hamper adherence to therapy and significantly
increase the overall costs of health care.
In recent years, the median survival of stage IV patients
with lung cancer has increased16–18 due to the use of better
staging tools and the introduction of new therapeutic agents
available in different lines of treatment (Figure 2). As patient
life expectancy has increased, there has been a corresponding
increase in patients presenting with bone metastases.
In the absence of any specific data on survival of
patients with lung cancer with bone as the only metastatic
site, it may be possible to extrapolate evidence from other
solid tumors showing longer survival of patients with metas-
tases in bone only, when compared with patients with liver
and brain metastases.19,20
METHODS
An expert panel of European clinical oncologists and lung
cancer specialists convened for two face-to-face meetings de-
signed to review available evidence on the efficacy of bisphos-
phonates (BPs) in lung cancer and to develop recommendations
based on published literature and clinical practice experiences.
The initial draft that was created from minutes of an advisory
panel meeting was critically revised during a second face-to-face
meeting of the European experts and additionally edited in
multiple revision rounds by all authors, until consensus was
reached. The authors were selected as a panel of expert clini-
cians from across the European Union, each contributing spe-
cific information regarding BP management of patients with
lung cancer, in a joint effort to produce recommendations re-
flecting the treatment options across the entire European Union.
BONE METASTASES AND QOL
SREs are associated with a loss of mobility, indepen-
dence and social functioning, and a decrease in QoL. The
Functional Assessment of Cancer Treatment-General analysis
found a significant reduction in physical, functional, and
emotional well being in prostate cancer patients who experi-
enced an SRE, when compared with those who did not.21,22
Assessing QoL changes due to SREs is currently based on
tools for other cancers.23,24 A specific tool for measuring the
QoL in patients with advanced lung cancer and bone metas-
tases should be developed and validated.
BP TREATMENT OF BONE METASTASES
The treatment of bone metastases usually involves symp-
tomatic support (analgesics and surgery), medical anticancer
treatment (chemotherapy and radiotherapy), and BPs to manage
symptoms and maintain bone integrity.25,7 Treatment with BPs
has been shown to be effective in reducing the incidence and
delaying the onset of SREs in patients with bone metastases in
a variety of solid tumors, including NSCLC.9–11,26–29 BPs bind
to bone at sites of active bone metabolism and inhibit osteoclast-
mediated bone resorption.30
FIGURE 1. Graph of data from Rosen et al.76 describing the
total percentage of patients experiencing skeletal-related
events (SREs; green). Also indicated is the percentage of pa-
tients suffering pathologic fracture (pink), requiring radio-
therapy (dark blue), undergoing surgical intervention (light
blue), or experiencing spinal cord compression (gray).
FIGURE 2. Treatment algorithm for advanced non-small
cell lung cancer (NSCLC). The treatment scheme was devel-
oped by the authors based on current treatment recommen-
dations and their own clinical experience. Patients in perfor-
mance status 0 to 2 should undergo chemotherapy as 1st
line treatment. Chemotherapy should be supported by the
use of bisphosphonates. Also for 2nd and 3rd line therapy, a
combination of chemotherapeutics or the tyrosine kinase
inhibitor erlotinib with bisphosphonates is recommended. In
the performance status 3 to 4, patients with lung cancer
may be treated with bisphosphonates on an individual basis.
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BPs are synthetic analogs of inorganic pyrophosphate31
but stable and resistant to hydrolysis by blood phosphatases.32
Because of their affinity for Ca2, they bind quickly and spe-
cifically to hydroxyapatite, particularly in areas of osteoclastic
resorption. They accumulate in the resorption space under oste-
oclasts, exposing them to elevated BP concentrations.33,34
Nonamino BPs such as etidronate and clodronate are
metabolized to cytotoxic adenosine triphosphate analogs in-
ducing osteoclast cell death.35–37 Conversely, amino-BPs
such as ibandronate, risedronate, pamidronate, and zoledronic
(ZOL) acid are much more potent in vitro than nonamino
compounds30 and act by inhibiting farnesyl pyrophosphate
synthase, an enzyme of the mevalonate pathway. ZOL acid is
the BP with the highest relative inhibitory potency in vivo
and in vitro known to date. The inhibition of the farnesyl
pyrophosphate synthase disrupts the formation of farnesyl
diphosphate and geranylgeranyl diphosphate38–40 molecules,
which are involved in prenylation, a posttranslational protein
modification resulting in attachment to the cell membrane41
(Figure 3). This localizes proteins in appropriate cell regions
and mediates their biologic activity. Proteins involved in-
clude the small GTPases, Ras, Rac, and Rho, which play key
roles in regulating osteoclast function and events in bone
resorption.42 Farnesyl pyrophosphate synthase inhibition ul-
timately leads to osteoclast apoptosis.
Among the BPs currently available, only ZOL has
demonstrated a delay in the onset and a reduction in the
incidence of SREs, when compared with placebo, and sus-
tained and significant reduction of bone-related pain in pa-
tients with lung cancer with bone metastases.9,29 In a double-
blind, placebo-controlled, 21-month trial, 773 patients with
bone metastases from solid tumors, including patients with
lung cancer (244 with NSCLC and 38 with small cell lung
cancer [SCLC]) were given 4 mg ZOL every 3 weeks. ZOL
reduced the risk of developing the SRE at 21 months by 31%
(hazard ratio [HR]  0.693, p  0.003).9,29 Treatment with
IV ZOL 4 mg every 3 to 4 weeks also delayed the onset of
SREs, extending the time to first SRE by nearly 3 months
relative to placebo (236 versus 155 days; p 0.009) (Figures
4 and 5).
These findings are further supported by a retrospective
study of 2539 patients with lung cancer with bone metastases
(2174 nontreated and 365 treated with ZOL) as reported by
Hatoum et al.43 This study used data derived from a claims
database of 80 health plans across the United States between
2002 and 2006. They found that in patients with lung cancer
treated with intravenous (IV) ZOL 4 mg every 3 to 4 weeks,
FIGURE 4. Graph based on data from Rosen et al.76 shows
that zoledronic acid reduced the proportion of patients with
a skeletal-related events (SRE) across all types of SRE.
FIGURE 5. Graph of data from Rosen et al. demonstrates
that zoledronic acid increased the median time to the first
skeletal-related event (SRE).29
FIGURE 3. Cellular mechanisms of osteoclast-mediated
bone resorption: cancer cells produce factors that stimulate
both osteoclast and osteoblast activity. Overproduction of
cytokines with osteoclast activation function results from in-
teraction between cancer cells and stromal cells. Interleukin
(IL)-6, IL-11, IL-1, tumor necrosis factor (TNF), and mac-
rophage colony-stimulating factor (M-CSF) are produced
predominantly by stromal cells, whereas hepatocyte growth
factor (HGF), macrophage inflammatory protein (MIP)-1,
MIP-1, IL-1, osteopontin (OPN), IL-6, and parathyroid hor-
mone-related protein are primarily produced by myeloma
cells. Receptor activator of NF-kappaB (RANK) ligand
(RANKL), a potent activator of osteoclasts, is expressed and
secreted by stimulated stromal cells. RANKL binds to RANK
on the surface of precursor and mature osteoclasts, activat-
ing bone resorption. When the ratio of RANKL/osteoprote-
gerin (OPG) is skewed in favor of RANKL, the normal regula-
tory effect of OPG is bypassed. This results in increased
osteoclastogenesis and osteoclast function. The disruption of
this RANK/RANKL/OPG axis is regarded as the main cause of
the progression of bone metastases.
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the risk of SREs was reduced by 30 to 40% (odds ratio [OR]
0.727; 95% CI  0.594–0.890) and the time from diagnosis
to the first bone complication was increased by 85% (log
regression model, 95% CI 60.6–114.2%).
CURRENT GUIDELINES FOR BP USE IN LUNG
CANCER SETTINGS ACROSS EUROPE
Most recent American and European treatment guide-
lines only address BP use in other cancer types, such as breast
cancer44 or multiple myeloma.25,45,46 Although the National
Comprehensive Cancer Network practice guidelines for 2008
do mention BP treatment for patients with lung cancer, it is
only recommended for alleviation of diffuse bone pain, as
part of general supportive care for all cancer patients.47
No European guidelines currently exist addressing BP
use for patients with lung cancer with respect to the preven-
tion or delay of SREs. Nevertheless, an international panel of
experts, examining the results presented by Rosen et al.9,29
(Figure 2), recommended that patients with lung cancer with
bone metastases and a reasonable chance of benefiting (e.g.,
expected survival times and performance status) should be
considered for ZOL treatment.48 A separate group of inter-
national experts, looking at the same disease setting, further
recommended screening for bone metastases at the initial
diagnosis and staging, to allow more timely and effective
treatment of bone metastases with bone-targeting therapy.49
EXPERT RECOMMENDATIONS FOR BP USE IN
THE LUNG CANCER SETTING
In response to the variations that exist across Europe
regarding the role of BPs in the treatment of lung cancer, a
panel of European experts met to examine the current evi-
dence and to agree on specific treatment recommendations for
clinicians treating patients with lung cancer with bone me-
tastases (Table 1).
DETECTION AND MONITORING OF BONE
METASTASES IN PATIENTS WITH
LUNG CANCER
Because of the morbidity associated with SREs, diag-
nosis and early treatment of bone metastases are vital to
maintain the patients’ QoL and functional independence.
Current recommendations by ESMO advise that bone scans
should only be performed during the staging of lung cancer in
those patients who present with bone pain or clinical charac-
teristics consistent with the existence of bone metastases.50
Nevertheless, bone metastases may be asymptomatic in the
early stage, and waiting until patients develop bone pain may
result in underdiagnosis of bone metastases that could result
in a lost treatment opportunity in this setting. Failure to detect
bone metastases may lead to an inconsistent or incomplete
staging and also result in less effective treatment strate-
gies.49,51 Patients with asymptomatic bone metastases may
have an increased benefit from BP therapy, when compared
with those with symptomatic bone metastases, as demon-
strated in a study of prostate cancer patients.14
Analysis of the incidence of bone metastases in patients
with NSCLC using bone scans over a period of 15 years has
yielded different results, ranging from 8 to 34%.7 Neverthe-
less, after the development of more sensitive positron emis-
sion tomography (PET) technology, the incidence of bone
metastases was more accurately estimated at 24% and 30% in
American and Japanese populations, respectively.5–7 Higher
sensitivity for detecting bone metastases is also provided by
whole body magnetic resonance imaging. To monitor patients
for the development of bone metastases, a convenient, radi-
TABLE 1. Summary of the Expert Panel Recommendations
on the BP Use in Patients with Lung Cancer
Diagnosis of bone metastases Patients with lung cancer should
be investigated for bone
metastases at the initial
staging of disease to assess
symptomatic and to screen for
asymptomatic bone
metastases, to allow accurate
monitoring of progression of
bone disease, and to initiate
bone-specific therapy
Bone assessment of patients
with lung cancer should
ideally be based on PET scan.
If not available, bone scan
should be used




treatment must be considered
part of the treatment to
prevent and delay the
occurrence of further bone
metastases and SREs and to
relieve pain, where present
Initiation of BP therapy In patients with lung cancer
(NSCLC and SCLC) who
develop bone metastases
during the course of their
disease, bisphosphonates
should be added to their
treatment. A comprehensive
dental examination before the
start of treatment is
recommended
Duration of BP therapy Bisphosphonate treatment in
patients with lung cancer
should be continued for as
long as it is practically
feasible in the absence of any
significant adverse effects
Combination with other therapies Combination of bisphosphonates
and chemotherapy is
generally well tolerated,
based on the published safety
precautions, and may have
synergistic effects
Final recommendations Based on the currently available
data, there is consensus to
recommend ZOL acid for the
therapy of patients with lung
cancer with bone metastases
BP, bisphosphonates; PET, positron emission tomography; NSCLC, non-small cell
lung cancer; SCLC, small cell lung cancer; ZOL, zoledronic.
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ation-free, and easy to repeat method is essential. Research on
such methods should be encouraged.
The expert panel strongly recommends screening of
patients with NSCLC for bone metastases at the initial stag-
ing of disease, to detect asymptomatic bone metastases and
allow accurate tracking of disease progression. Although PET
scans were considered distinctly superior to bone scans in the
detection of bone metastases, access to the appropriate diag-
nostic tools may currently be limited for some clinicians.
Therefore, it is advised that every patient diagnosed with lung
cancer should have a bone scan at initial staging, unless they
have already received a PET scan.
INITIATION OF BP TREATMENT
Findings of a recent study suggest that initiation of BP
treatment for bone metastases in NSCLC, early in the course
of the disease, is the optimal treatment strategy.15 Indeed,
initiation of BP treatment before the onset of SREs has also
been found to be the most effective strategy in the treatment
of bone metastases in other solid tumor settings, such as
breast and prostate cancer.52,53 Therefore, BPs should ideally
be used as part of first-line therapy, alongside other treatment
strategies, to delay or prevent progression of bone disease and
SREs, and to relieve pain, where present (Figure 2).
Although, at the current time, there are in vitro data
addressing the positive interactions that may occur between BPs
and other first-line drugs, the expert panel reached a consensus
for concomitant BP use in this setting. Preliminary evidence
available with ZOL suggests that this may even lead to improved
treatment outcomes similar to those in other solid tumors.54 In a
subset of the Adjuvant Zoledronic Acid to Reduce Recurrence
clinical trial in breast cancer patients, ZOL combined with
neoadjuvant chemotherapy achieved a significantly greater
shrinkage of the primary tumor than chemotherapy alone.54
Although BP therapy should be considered an option in all
patients with advanced lung cancer, the panel recommends that
BP treatment decisions for patients with poor Eastern Cooperative
Oncology Group performance status (3–4) should be taken
on an individual basis, addressing primarily palliative
endpoints.
DURATION OF TREATMENT WITH BPS
In the absence of available data regarding the optimal
duration of BP treatment for bone metastases in patients with
lung cancer, the panel advises that BP treatment during first-
and second-line therapy should be continued for as long as it
proves feasible. Progression of bone disease or the occur-
rence of an SRE alone should not necessarily trigger discon-
tinuation of BP therapy, because this might influence the
occurrence of subsequent SREs.13,55
SELECTION OF PATIENTS FOR BP THERAPY
With the emergence of more effective NSCLC treat-
ments, a subgroup of patients with advanced lung cancer and
bone metastases will survive for more than a year after
diagnosis and could potentially benefit from BP treatment.
Therefore, it is strongly advised to start patients on BP
treatment before the emergence of symptoms of bone metas-
tases to reduce the number or delay the occurrence and/or
progression of SREs. In addition to the existing data on
prognostic factors or predictive markers,56 research should be
encouraged to identify a patient subgroup with better out-
come based on clinical and biologic characteristics.
Bone markers may provide a powerful laboratory tool
for monitoring patients with bone metastases and could pos-
sibly be used to select for this long-lived subgroup of pa-
tients. A retrospective analysis conducted by Hirsh et al.15
revealed a statistically significant correlation between ZOL
treatment and increased survival versus placebo in patients
with NSCLC with high-baseline amino-terminal crosslinking
telopeptide of collagen levels (Figure 6). Nevertheless, such
markers will need to be prospectively validated before im-
plementation, and therefore at this stage the panel does not
recommend the use of bone markers in the clinical routine
treatment of patients with lung cancer with bone metastases.
Based on the only published studies,9,29 which included
patients with SCLC with bone metastases, the panel suggests
that these patients should be treated following the same
recommendations as patients with NSCLC.
SELECTION OF BPS
Currently, ZOL has the best data in lung cancer, both in
vitro and in the clinical setting. Other BPs are being explored
in phase II studies for use in lung cancer. The panel strongly
recommends ZOL (4 mg IV/3–4 weeks) for the therapy for
patients with lung cancer with bone metastases in the absence
of randomized clinical trial data with other BPs.
QOL AND PHARMACOECONOMIC
CONSIDERATIONS IN BP TREATMENT
SREs lead to a loss of functional capacity, an increase
in emergency care, days of hospitalization, and increased
need for external medical services and further indirect social
costs. This typically results in significantly increased treat-
ment costs57 (Figure 7).
Several recent studies have investigated the economic
value of treatment with ZOL, when compared with placebo in
patients with lung cancer with bone metastases in the United
Kingdom, France, and Germany.58–60 In each case, treatment
with ZOL was found to improve QoL and provide a clear
economic benefit. For example, the use of ZOL was associ-
ated with a reduction in SRE costs per person of €2486 in
Germany and €1652 in the United Kingdom.59
Therefore, it is strongly recommended that, both for the
QoL of the patient and for overall cost savings, the long-term
cost of BP treatment should be considered by health care
systems when defining the therapeutic strategy in this clinical
setting.
SAFETY OF BPS IN PATIENTS WITH
LUNG CANCER
Being almost entirely cleared by the kidneys, IV BPs have
been associated with reports of renal dysfunction. Factors that
may increase the potential for deterioration in renal function
include dehydration, preexisting renal impairment, concomitant
use of other nephrotoxic drugs, and the lack of adherence to the
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recommended infusion time. The product label for ZOL acid,
i.e., the only BP licensed in Europe for the treatment of bone
metastases in patients with lung cancer, recommends to assess
the serum creatinine and creatinine clearance before starting
treatment and monthly before each dose. Dose adjustment is
recommended in patients with mild to moderate renal impair-
ment, whereas ZOL acid is not recommended in patients with
severe renal impairment. Although osteonecrosis of the jaw
(ONJ) is rare in patients with cancer-induced bone disease and is
usually associated with dental trauma or suboptimal dental
hygiene,61,62 a dental examination by a qualified dentist should
be performed before initiation of BP treatment in patients with
lung cancer, to avoid any occurrence of ONJ.62 Recent studies
on ONJ during BP treatment showed that preventive measures
and oral health care can reduce the incidence by almost three-
fold.63 In addition, antibiotic prophylaxis may prevent ONJ
occurrence after dental procedures.62 Ripamonti et al.62 observed
a reduction from 3.2 to 1.3% when comparing pre- and
postimplementation of a preventative measures program. So far,
there have been no reports of ONJ in patients with lung cancer.
FUTURE DIRECTIONS FOR BP USE
Recent evidence, both in vitro and from some early
clinical studies, has shown that ZOL may have additional ther-
apeutic activities beyond the reduction in the risk of SREs or
pain relief.64 Preclinical tests have shown that ZOL can impede
tumor growth, both in the bone and overall.65 This may be due
to several additional effects reported for some BPs (particularly
ZOL) on tumor migration, adhesion, and invasion across mem-
branes,66 or their antiangiogenesis or immunomodulatory activ-
ities.67–72 Interestingly, a study examining the in vitro and in
vivo effect of ZOL on a murine lung cancer cell line, which
simulates NSCLC, found that the drug had an antiproliferative
effect in vivo, arresting cells at the S/G2/M phase of the cell
cycle.73 Further, ZOL-treated mice in this study were found to
have slower tumor growth and a significantly longer lifespan
than those who did not receive treatment.
The antitumor effect of BP treatment has already been
observed at a clinical level in a number of other malignancies.
In a subset analysis of patients with renal cell carcinoma,
ZOL was found to delay disease progression, when compared
with placebo.74 Most notably, a study by Gnant et al.64 of
premenopausal women with endocrine-positive breast cancer
found that the addition of ZOL to adjuvant endocrine therapy
significantly prolonged the disease-free and recurrence-free
survival periods, when compared with adjuvant endocrine
therapy alone (disease-free survival increased by 36%, HR 
0.64; p  0.01; relapse-free survival increased by 35%,
FIGURE 6. Survival patterns of patients with non-small cell lung cancer (NSCLC) based on NTX levels at baseline. Graphs are
adapted with permission from J Thorac Oncol Copyright 2008.15 NTX, amino-terminal crosslinking telopeptide of collagen.
FIGURE 7. Kaplan Meier estimated cumulative costs of skel-
etal-related event (SRE)- and non SRE-related care. Graphs
are adapted with permission from J Thorac Oncol Copyright
2006.57
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HR  0.65, p  0.015). Evidence of increased tumor shrink-
age from the Adjuvant Zoledronic Acid to Reduce Recur-
rence trial54 and data from the ZO-FAST trial in breast cancer
support a clinically relevant antitumor activity of ZOL.75 The
available evidence suggests that ZOL may also act by directly
affecting tumor progression, possibly in synergy with other
therapeutic treatments.52,54
Currently, a large, phase III, international randomized
prospective trial is underway examining the efficacy of ZOL
in delaying or preventing bone metastases in patients with
successfully treated stage III NSCLC.
SUMMARY OF PANEL RECOMMENDATIONS
Y Patients with lung cancer should be investigated for
bone metastases at the initial staging of disease to assess
symptomatic and to screen for asymptomatic bone me-
tastases, to allow accurate monitoring of progression of
bone disease, and to initiate bone-specific therapy.
Y Bone assessment of patients with lung cancer should
ideally be based on PET scan. If not available, bone scan
should be used.
Y In patients with lung cancer (NSCLC and SCLC) diag-
nosed with bone metastases, BP treatment must be
considered part of the treatment to prevent and delay the
occurrence of further bone metastases and SREs and to
relieve pain where present. BP treatment in patients with
lung cancer should be continued for as long as it is
practically feasible in the absence of any significant
adverse effects.
Y In patients with lung cancer (NSCLC and SCLC) who
develop bone metastases during the course of their
disease, BPs should be added to their treatment. A
comprehensive dental examination before the start of
treatment is recommended.
Y Combination of BPs and chemotherapy is generally well
tolerated, based on the published safety precautions, and
may have synergistic effects.
Y Based on the currently available data, there is consensus
to recommend ZOL for the therapy for patients with
lung cancer with bone metastases.
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